Lih Kin Khor1, Hoi Yin Loi1, Arvind Kumar Sinha1, Kian Ti Tong2, Boon Cher Goh3, Kwok Seng Loh4, Suat-Jin Lu5. 1. Department of Diagnostic Imaging, National University Hospital, Singapore. 2. Department of Nuclear Medicine and PET, Singapore General Hospital, Singapore. 3. Department of Hematology and Oncology, National University Hospital, Singapore. 4. Department of Otolaryngology, National University Hospital, Singapore. 5. Nuclear Medicine and PET Centre, Mount Elizabeth Hospital, Singapore.
Abstract
BACKGROUND: Increased somatostatin receptor (SSTR) expression in patients with undifferentiated nasopharyngeal carcinoma (NPC) has been demonstrated with receptor autoradiography, (111) In-Octreotide scintigraphy, and (68) Ga-DOTA-TOC positron emission tomography (PET)/CT imaging. We sought to compare and correlate the uptake of fluorodeoxyglucose (FDG) and DOTA-NOC in undifferentiated NPC to ascertain the possible role of (68) Ga-DOTA-NOC PET/CT as a new imaging biomarker and to assess whether targeted peptide receptor radionuclide therapy is a feasible treatment option. METHODS: After obtaining approval from our institutional review board, 4 patients with biopsy proven nonkeratinizing undifferentiated NPC who had just undergone routine staging/restaging (18) F-FDG PET/CT imaging were prospectively and consecutively recruited for (68) Ga-DOTA-NOC PET/CT imaging. Of these 4 patients, 3 were newly diagnosed with untreated NPC, whereas 1 patient was diagnosed with a case of recurrent NPC with previous treatment. These patients subsequently underwent (68) Ga-DOTA-NOC PET/CT within 10 days from the (18) F-FDG PET/CT to ensure lesion comparability. Tracer uptake in tumor lesions were assessed visually and semiquantitatively by measuring maximum standardized uptake values (SUVmax). RESULTS: There were 12 FDG-avid lesions of which 7 showed avid uptake of DOTA-NOC greater than liver uptake, whereas 5 showed low uptake of DOTA-NOC less than liver uptake. Subset analysis of the FDG-avid lesions at the primary and recurrent sites showed that all the FDG-avid primary tumors in the nasopharynx showed avid uptake of DOTA-NOC. On the contrary, the case of recurrent NPC showed avid FDG uptake but low DOTA-NOC uptake. Subset analysis of the suspicious FDG-avid cervical lymph nodes showed that 50% of them demonstrated avid DOTA-NOC uptake greater than liver uptake, whereas the remaining demonstrated low-grade DOTA-NOC uptake less than liver uptake. The 2 subcentimeter cervical lymph nodes that showed low-grade uptake of FDG lower than mediastinal blood pool activity were deemed to be reactive/inflammatory and showed low-grade uptake of DOTA-NOC. CONCLUSION: This study highlights the potential of (68) Ga-DOTA-peptide PET/CT as a new molecular biomarker for newly diagnosed undifferentiated NPC, and less so for recurrent NPC and metastatic nodes. This potentially opens up new diagnostic and therapeutic options in the management of undifferentiated NPC.
BACKGROUND: Increased somatostatin receptor (SSTR) expression in patients with undifferentiated nasopharyngeal carcinoma (NPC) has been demonstrated with receptor autoradiography, (111) In-Octreotide scintigraphy, and (68) Ga-DOTA-TOC positron emission tomography (PET)/CT imaging. We sought to compare and correlate the uptake of fluorodeoxyglucose (FDG) and DOTA-NOC in undifferentiated NPC to ascertain the possible role of (68) Ga-DOTA-NOC PET/CT as a new imaging biomarker and to assess whether targeted peptide receptor radionuclide therapy is a feasible treatment option. METHODS: After obtaining approval from our institutional review board, 4 patients with biopsy proven nonkeratinizing undifferentiated NPC who had just undergone routine staging/restaging (18) F-FDG PET/CT imaging were prospectively and consecutively recruited for (68) Ga-DOTA-NOC PET/CT imaging. Of these 4 patients, 3 were newly diagnosed with untreated NPC, whereas 1 patient was diagnosed with a case of recurrent NPC with previous treatment. These patients subsequently underwent (68) Ga-DOTA-NOC PET/CT within 10 days from the (18) F-FDG PET/CT to ensure lesion comparability. Tracer uptake in tumor lesions were assessed visually and semiquantitatively by measuring maximum standardized uptake values (SUVmax). RESULTS: There were 12 FDG-avid lesions of which 7 showed avid uptake of DOTA-NOC greater than liver uptake, whereas 5 showed low uptake of DOTA-NOC less than liver uptake. Subset analysis of the FDG-avid lesions at the primary and recurrent sites showed that all the FDG-avid primary tumors in the nasopharynx showed avid uptake of DOTA-NOC. On the contrary, the case of recurrent NPC showed avid FDG uptake but low DOTA-NOC uptake. Subset analysis of the suspicious FDG-avid cervical lymph nodes showed that 50% of them demonstrated avid DOTA-NOC uptake greater than liver uptake, whereas the remaining demonstrated low-grade DOTA-NOC uptake less than liver uptake. The 2 subcentimeter cervical lymph nodes that showed low-grade uptake of FDG lower than mediastinal blood pool activity were deemed to be reactive/inflammatory and showed low-grade uptake of DOTA-NOC. CONCLUSION: This study highlights the potential of (68) Ga-DOTA-peptide PET/CT as a new molecular biomarker for newly diagnosed undifferentiated NPC, and less so for recurrent NPC and metastatic nodes. This potentially opens up new diagnostic and therapeutic options in the management of undifferentiated NPC.
Authors: M Unterrainer; C Eze; H Ilhan; S Marschner; O Roengvoraphoj; N S Schmidt-Hegemann; F Walter; W G Kunz; P Munck Af Rosenschöld; R Jeraj; N L Albert; A L Grosu; M Niyazi; P Bartenstein; C Belka Journal: Radiat Oncol Date: 2020-04-21 Impact factor: 3.481
Authors: Matt Lechner; Volker H Schartinger; Christopher D Steele; Wen Long Nei; Marc Lucas Ooft; Liesa-Marie Schreiber; Christodoulos P Pipinikas; Grace Tin-Yun Chung; Yuk Yu Chan; Feng Wu; Ka-Fai To; Chi Man Tsang; Wayne Pearce; Daniele Morelli; Martin Philpott; Liam Masterson; Reshma Nibhani; Graham Wells; Christopher G Bell; Julia Koller; Susanne Delecluse; Yim Ling Yip; Jacklyn Liu; Cillian T Forde; Martin D Forster; Amrita Jay; József Dudás; Annika Krapp; Simon Wan; Christian Uprimny; Susanne Sprung; Johannes Haybaeck; Tim R Fenton; Kerry Chester; Christina Thirlwell; Gary Royle; Teresa Marafioti; Rajeev Gupta; Sagung Rai Indrasari; Camelia Herdini; Mohd Afiq Mohd Slim; I Indrawati; Liam Sutton; Renske Fles; Bing Tan; Joe Yeong; Amit Jain; Shuting Han; Haitao Wang; Kelvin S H Loke; Wan He; Ruilian Xu; Hongtao Jin; Zhiqiang Cheng; David Howard; Peter H Hwang; Quynh-Thu Le; Joshua K Tay; Robert B West; Sai Wah Tsao; Tim Meyer; Herbert Riechelmann; Udo Oppermann; Henri-Jacques Delecluse; Stefan M Willems; Melvin L K Chua; Pierre Busson; Kwok Wai Lo; Guido Wollmann; Nischalan Pillay; Bart Vanhaesebroeck; Valerie J Lund Journal: Nat Commun Date: 2021-01-05 Impact factor: 14.919
Authors: Oscar Emanuel; Jacklyn Liu; Volker H Schartinger; Wen Long Nei; Yuk Yu Chan; Chi Man Tsang; Herbert Riechelmann; Liam Masterson; Johannes Haybaeck; Udo Oppermann; Stefan M Willems; Marc L Ooft; Guido Wollmann; David Howard; Bart Vanhaesebroeck; Valerie J Lund; Gary Royle; Melvin L K Chua; Kwok Wai Lo; Pierre Busson; Matt Lechner Journal: Cancers (Basel) Date: 2021-09-30 Impact factor: 6.639